Mateon Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
September 20 2016 - 3:45PM
Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage
biopharmaceutical company developing vascular disrupting agents for
the treatment of orphan oncology indications, today announced it
will present an overview of the company at the Ladenburg Thalmann
2016 Healthcare Conference on Tuesday, September 27, 2016 at 4:00
p.m. eastern time at the Sofitel New York.
To listen to a live webcast of the presentation, please visit
the Company's website, www.mateon.com. Under the "Investors &
News" tab, select the link to "Events & Presentations." A
replay of the webcast will be available at this same location for a
period of time following the conclusion of the live event.
About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking
to realize the full potential of vascular targeted therapy (VTT) in
oncology. VTT includes vascular disrupting agents (VDAs) such as
the investigational drugs that Mateon is developing, and
anti-angiogenic agents (AAs), a number of which are FDA-approved
and widely used in cancer treatment. These two approaches
have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer
therapy by employing these two complementary approaches
simultaneously. When utilized this way, VDAs obstruct
existing blood vessels in the tumor leading to significant central
tumor cell death while AAs prevent the formation of new tumor blood
vessels.
Mateon is committed to leveraging our intellectual property and
the product development expertise of our highly skilled management
team to enable VTT to realize its true potential and to bring
much-needed new therapies to cancer patients worldwide.
CONTACT for investors and media:
ir@mateon.com
650-635-7000